Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients
- 1 March 1990
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 40 (3_part_1) , 456
- https://doi.org/10.1212/wnl.40.3_part_1.456
Abstract
ACC-9653, a prodrug of phenytoin synthesized to be water soluble, is converted to phenytoin by phos-phatases. In this study, 43 patients received ACC-9653 IV or IM. Side effects were transient and minor. The conversion half-lives of ACC-9653 after intravenous and intramuscular administration averaged 8.4 and 32.7 minutes, respectively. Peak phenytoin concentrations occurred 42 minutes after IV and 151 minutes after IM administration.This publication has 12 references indexed in Scilit:
- Phenytoin Prodrugs IV: Hydrolysis of Various 3-(Hydroxymethyl)phenytoin EstersJournal of Pharmaceutical Sciences, 1984
- Phenytoin Prodrugs III: Water-Soluble Prodrugs for Oral and/or Parenteral UseJournal of Pharmaceutical Sciences, 1984
- Complications of intravenous phenytoin for acute treatment of seizures. Recommendations for usageJAMA, 1983
- Blood-brain barrier transfer and cerebral uptake of antiepileptic drugsClinical Pharmacology & Therapeutics, 1982
- POSTOPERATIVE EPILEPSY: A DOUBLE-BLIND TRIAL OF PHENYTOIN AFTER CRANIOTOMYThe Lancet, 1980
- Intravenous phenytoin in acute treatment of seizuresNeurology, 1979
- Compliance and Variability of Plasma Phenytoin Levels in Epileptic PatientsTherapeutic Drug Monitoring, 1979
- Maintenance of Therapeutic Phenytoin Plasma Levels via Intramuscular AdministrationAnnals of Internal Medicine, 1976
- Sudden death following intravenous sodium diphenylhydantoinAmerican Heart Journal, 1976
- The cardiocirculatory changes caused by intravenous Dilantin and its solventAmerican Heart Journal, 1967